ObjectiveTo observe the clinical effect of azithromycin combined with Fukangjian agent in the treatment of patients with mycoplasma-infective pelvic inflammatory disease. MethodsA total of 174 patients with mycoplasma-infective pelvic inflammatory disease admitted to our hospital from February 2016 to January 2018 were selected as subjects and randomly divided into observation group and control group, with 87 cases in each group. Control group were treated with azithromycin, and observation group were treated with Fukangjian agent on the basis of therapeutic method of control group. The T lymphocyte subset levels and uterine hemodynamics indicators of the two groups were compared before and after treatment. The clinical curative effect of the two groups was compared. ResultsThe total effective rate of observation group (94.25%) was higher than that of the control group (86.21%), the difference was statistically significant (P＜0.05). After 4 weeks of treatment, the levels of CD4+, CD4+/CD8+, RI, PI and Vmin in peripheral blood of the two groups were significantly increased, while the CD8+ level was significantly decreased; and the levels of CD4+, CD4+/CD8+, RI, PI and Vmin in peripheral blood of observation group were significantly higher than that of control group, while the CD8+ level was significantly lower than of control group, the difference were statistically significant (P＜0.05). The incidence of adverse reactions of the observation group (8.05%), higher than 5.75% of the control group, but the difference was not statistically significant (P＞0.05). ConclusionAzithromycin combined with Fukangjian agent is effective in the treatment of mycoplasma-infective pelvic inflammatory disease. It can promote immune functionand, improve uterine hemodynamics, facilitate rehabilitation and show high clinical safety.

无